Marathon Capital Management Zymeworks Inc. Transaction History

Marathon Capital Management

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$4.82 - $7.7 $99,243 - $158,543	-20,590 Reduced 43.04%	27,250 $144,000
Q1 2022 May 13, 2022	BUY	$6.0 - $16.98 $21,000 - $59,430	3,500 Added 7.89%	47,840 $313,000
Q4 2021 Feb 09, 2022	SELL	$15.19 - $29.33 $32,278 - $62,326	-2,125 Reduced 4.57%	44,340 $727,000
Q3 2021 Nov 15, 2021	BUY	$27.35 - $37.28 $17,230 - $23,486	630 Added 1.37%	46,465 $1.35 Million
Q2 2021 Aug 16, 2021	BUY	$26.5 - $38.23 $6,625 - $9,557	250 Added 0.55%	45,835 $1.59 Million
Q1 2021 May 14, 2021	BUY	$29.83 - $56.81 $184,946 - $352,222	6,200 Added 15.74%	45,585 $1.44 Million
Q4 2020 Feb 08, 2021	SELL	$39.12 - $54.99 $260,147 - $365,683	-6,650 Reduced 14.45%	39,385 $1.86 Million
Q3 2020 Nov 16, 2020	SELL	$29.21 - $46.58 $47,466 - $75,692	-1,625 Reduced 3.41%	46,035 $2.14 Million
Q2 2020 Aug 14, 2020	SELL	$33.67 - $40.0 $33,670 - $40,000	-1,000 Reduced 2.06%	47,660 $1.72 Million
Q1 2020 May 15, 2020	SELL	$24.28 - $49.8 $15,782 - $32,369	-650 Reduced 1.32%	48,660 $1.73 Million
Q4 2019 Feb 14, 2020	SELL	$24.84 - $45.46 $77,625 - $142,062	-3,125 Reduced 5.96%	49,310 $2.24 Million
Q3 2019 Nov 13, 2019	BUY	$22.78 - $29.08 $5,922 - $7,560	260 Added 0.5%	52,435 $1.3 Million
Q2 2019 Jul 25, 2019	BUY	$15.0 - $22.49 $782,625 - $1.17 Million	52,175 New	52,175 $1.15 Million

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $905M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Marathon Capital Management, based on Form 13F filings with the SEC.

Stay updated on Marathon Capital Management with notifications on news.